Amended Statement of Ownership (sc 13g/a)
February 12 2020 - 11:18AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
Schedule 13G
Under the Securities Exchange Act of
1934
(Amendment No.: 2)*
Name of issuer: Regeneron
Pharmaceuticals Inc
Title of Class of
Securities: Common Stock
CUSIP Number: 75886F107
Date of Event Which Requires Filing of
this Statement: December 31, 2019
Check the appropriate box to designate
the rule pursuant to which this Schedule is filed:
☒ Rule 13d-1(b)
☐ Rule 13d-1(c)
☐ Rule 13d-1(d)
*The remainder of this
cover page shall be filled out for a reporting person's initial
filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information
which would alter the disclosures provided in a prior cover
page.
The information
required in the remainder of this cover page shall not be deemed to
be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that
section of the Act but shall be subject to all other provisions of
the Act (however, see the Notes).
(Continued on the
following page(s))
13G
CUSIP No.: 75886F107
1. NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
The Vanguard Group -
23-1945930
2. CHECK THE APPROPRIATE
[LINE] IF A MEMBER OF A GROUP
3. SEC USE ONLY
4. CITIZENSHIP OF PLACE OF
ORGANIZATION
Pennsylvania
(For questions 5-8, report the number
of shares beneficially owned by each reporting person with:)
5. SOLE VOTING POWER
120,348
6. SHARED VOTING POWER
23,068
7. SOLE DISPOSITIVE
POWER
6,116,133
8. SHARED DISPOSITIVE
POWER
136,170
9. AGGREGATE AMOUNT
BENEFICIALLY OWNED BY EACH REPORTING PERSON
6,252,303
10. CHECK BOX IF THE
AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
N/A
11. PERCENT OF CLASS
REPRESENTED BY AMOUNT IN ROW 9
5.79%
12. TYPE OF REPORTING
PERSON
IA
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
Schedule 13G
Under the Securities Act of 1934
Item 1(a) -
Name of Issuer:
Regeneron
Pharmaceuticals Inc
Item 1(b) -
Address of Issuer's Principal Executive Offices:
777 Old Saw Mill River
Road
Tarrytown, New York 10591-6707
Item 2(a) -
Name of Person Filing:
The Vanguard Group -
23-1945930
Item 2(b) –
Address of Principal Business Office or, if none, residence:
100 Vanguard Blvd.
Malvern, PA 19355
Item 2(c) –
Citizenship:
Pennsylvania
Item 2(d) -
Title of Class of Securities:
Common Stock
Item 2(e) -
CUSIP Number
75886F107
Item 3 - Type
of Filing:
This statement is
being filed pursuant to Rule 13d-1. An investment
adviser in accordance with §240.13d-1(b)(1)(ii)(E).
Item 4 -
Ownership:
(a) Amount Beneficially
Owned:
6,252,303
(b) Percent of Class:
5.79%
(c) Number of shares as to
which such person has:
(i) sole
power to vote or direct to vote: 120,348
(ii) shared
power to vote or direct to vote: 23,068
(iii) sole
power to dispose of or to direct the disposition
of: 6,116,133
(iv) shared
power to dispose or to direct the disposition
of: 136,170
Comments:
Item 5 -
Ownership of Five Percent or Less of a Class:
If this statement is
being filed to report the fact that as of the date hereof the
reporting person has ceased to be the beneficial owner of more than
5 percent of the class of securities, check the following ☐
Item 6 -
Ownership of More Than Five Percent on Behalf of Another
Person:
Not applicable
Item 7 -
Identification and Classification of the Subsidiary Which Acquired
The Security Being Reported on by the Parent Holding Company:
See Attached Appendix
A
Item 8 -
Identification and Classification of Members of Group:
Not applicable
Item 9 -
Notice of Dissolution of Group:
Not applicable
Item 10 -
Certification:
By signing below I
certify that, to the best of my knowledge and belief, the
securities referred to above were acquired and are held in the
ordinary course of business and were not acquired and are not held
for the purpose of or with the effect of changing or influencing
the control of the issuer of the securities and were not acquired
in connection with or as a participant in any transaction having
that purpose or effect, other than activities solely in connection
with a nomination under §240.14a-11.
Signature
After reasonable
inquiry and to the best of my knowledge and belief, I certify that
the information set forth in this statement is true, complete and
correct.
Date: February 10, 2020
By
/s/ Christine M.
Buchanan
Name: Christine M. Buchanan
Title: Principal
Appendix A
Vanguard Fiduciary Trust Company
("VFTC"), a wholly-owned subsidiary of The Vanguard Group, Inc., is
the beneficial owner of 91,833 shares or 0.08% of the Common
Stock outstanding of the Company as a result of its serving as
investment manager of collective trust accounts.
Vanguard Investments Australia, Ltd.
("VIA"), a wholly-owned subsidiary of The Vanguard Group, Inc., is
the beneficial owner of 71,498 shares or 0.06% of the Common Stock
outstanding of the Company as a result of its serving as investment
manager of Australian investment offerings.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Dec 2020 to Jan 2021
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jan 2020 to Jan 2021